PubRank

Stephane Culine

Author PubWeight™ 12.79‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009 1.99
2 Identification of pro-MMP-7 as a serum marker for renal cell carcinoma by use of proteomic analysis. Clin Chem 2008 1.60
3 Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. J Clin Oncol 2011 1.45
4 Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology 2011 1.15
5 Advanced seminoma--treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients. Cancer 2003 1.00
6 The use of estramustine phosphate in the modern management of advanced prostate cancer. BJU Int 2011 0.85
7 A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. Eur J Cancer 2011 0.85
8 Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen. Eur J Cancer 2012 0.85
9 Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium. Mar Drugs 2009 0.83
10 [Penile tumors]. Prog Urol 2004 0.79
11 Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site. Anticancer Res 2003 0.78
12 [Angiogenesis targeting in renal carcinomas]. Bull Cancer 2007 0.77
13 Phase II study of melphalan as a single-agent infused over a 24-hour period with individual adapted dosing in patients with recurrent epithelial ovarian cancer. Oncol Rep 2006 0.76
14 18F-Choline PET/CT and Prostate MRI for Staging Patients With Biochemical Relapse After Irradiation for Prostate Cancer. Clin Nucl Med 2015 0.75
15 [Chemotherapy of penile carcinomas]. Prog Urol 2005 0.75
16 [Testicular tumors]. Prog Urol 2004 0.75